Patent Coverage Leads Indian Drug Makers Into Ties With Foreign Firms
This article was originally published in PharmAsia News
Executive Summary
India's three year old ban on generic copies of drugs still under patent coverage has led the pharma industry to turn to inlicensing and strategic marketing deals with foreign companies. A pharma researcher said the deals offer higher margins, between 25 percent and 35 percent, without competition from other generics. Ranbaxy Laboratories has the largest number of ties with other drug makers, allowing it to launch 12 new products in the recent three month period. The ties also lower the amount of investments needed in the business and fewer risks. (Click here for more
You may also be interested in...
Mark Cuban ‘Very Involved’, Insists Generics Company CEO
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
Bharat Biotech To Make GSK’s Malaria Vaccine For WHO
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Irish Ad Code Covers OTC Devices And Herbals For First Time
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.
Need a specific report? 1000+ reports available
Buy Reports